Nuwellis (NASDAQ:NUWE) Raised to Hold at Wall Street Zen

Nuwellis (NASDAQ:NUWE) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuwellis in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Nuwellis Price Performance

NASDAQ:NUWE opened at $2.85 on Friday. The company has a market cap of $228,000.00, a P/E ratio of -0.00 and a beta of 0.29. Nuwellis has a 1 year low of $2.73 and a 1 year high of $577.50. The stock’s fifty day moving average price is $14.05 and its two-hundred day moving average price is $43.39.

Nuwellis (NASDAQ:NUWE) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($73.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($35.00) by ($38.15). The company had revenue of $2.40 million for the quarter, compared to analysts’ expectations of $2.09 million. Nuwellis had a negative return on equity of 32,351.83% and a negative net margin of 214.90%.

Institutional Trading of Nuwellis

A hedge fund recently raised its stake in Nuwellis stock. Sabby Management LLC boosted its position in Nuwellis, Inc. (NASDAQ:NUWE) by 149.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 89,685 shares of the company’s stock after acquiring an additional 53,791 shares during the quarter. Nuwellis accounts for approximately 0.2% of Sabby Management LLC’s portfolio, making the stock its 18th largest holding. Sabby Management LLC owned about 4.80% of Nuwellis worth $156,000 at the end of the most recent reporting period. 3.13% of the stock is currently owned by institutional investors and hedge funds.

About Nuwellis

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.